Tilray(US:TLRY) The Motley Fool·2025-12-14 22:00Core Insights - The cannabis industry is poised for increased profitability as shares of Tilray Brands surged 65% in a week, driven by investor optimism regarding potential regulatory changes from the Trump administration [1][5]. Regulatory Changes - President Trump is reportedly considering reclassifying marijuana from a Schedule I drug to a Schedule III drug, with a decision expected as soon as December 15 [3]. - Schedule I drugs are defined as having no accepted medical use and a high potential for abuse, while Schedule III drugs have moderate to low potential for dependence [4]. Financial Implications - A reclassification could facilitate cannabis companies' access to banking and traditional financial services, and allow them to claim federal tax deductions for business expenses currently disallowed [6]. - This regulatory shift is likely to enhance after-tax profits for Tilray and other cannabis producers, potentially leading to a more lucrative market environment [6].